CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture

Prostate

Volumn 34, Issue 3, 1998, Pages 162-168

  De Marzo, Angelo M ^a   Bradshaw, Chad ^a   Sauvageot, Jurgita ^a   Epstein, Jonathan I ^a   Miller, Gary J ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antigens, CD44; Metastasis; Prostatic intraepithelial neoplasia; Prostatic neoplasms

Indexed keywords

HERMES ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CYTOARCHITECTURE; DIAGNOSTIC VALUE; DOWN REGULATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD44; BONE NEOPLASMS; DOWN-REGULATION; HUMANS; LYMPH NODES; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0031981414     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K     Document Type: Article

References (45)

1. Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol 1988;23:273-279.
2. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
3. Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB: A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type 1 collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992; 116:521-531.
4. Thomas L, Etoh T, Stamenkovic I, Mihm MC Jr, Byers HR: Migration of human melanoma cells on hyaluronate is related to CD44 expression. J Invest Dermatol 1993;100:115-120.
5. Belitsos PC, Hildreth JE, August JT: Homotypic cell aggregation induced by anti-CD44(Pgp-1) monoclonal antibodies and related to CD44(Pgp-1) expression. J Immunol 1990;144:1661-1670.
6. Koopman G, van Kooyk Y, de Graaff M, Meyer CJ, Figdor CG, Pals ST: Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990;145:3589-3593.
7. Droll A, Dougherty ST, Chiu RK, Dirks JF, McBride WH, Cooper DL, Dougherty GJ: Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem 1995;270:11567-11573.
8. Zoller M: CD44: Physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 1995;73:425-438.
9. Joensuu H, Ristamaki R, Klemi PJ, Jalkanen S: Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 1993;68: 428-432.
10. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST: Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990;4:595-599.
11. Jalkanen S, Joensuu H, Klein P: Prognostic value of lymph node homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 1990;5:1549-1553.
12. Birch M, Mitchell S, Hart IR: Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991;51:6660-6667.
13. Faassen AE, Mooradian DL, Tranquillo RT, Dickinson RB, Letourneau PC, Oegema TR, McCarthy JB: Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen. J Cell Sci 1993;105:501-511.
14. Guo Y, Ma J, Wang J, Che X, Narula J, Bigby M, Wu M, Sy MS: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994;54:1561-1565.
15. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
16. Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, Pal ST: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-233.
17. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993;143:867-874.
18. Kaufmann M, Heider KH, Sinn HP, Vonminchwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-619.
19. Iida N, Bourguignon LY: New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995;162:127-133.
20. Heider KH, Dammrich J, Skroch-Angel P, Muller-Hermelink HK, Vollmers HP, Herrlich P, Ponta H: Differential expression of CD44 splice variants in intestinal-and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53:4197-4203.
21. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP: De-novo expression of CD44 and survival in gastric cancer. Lancet 1993;342:1019-1022.
22. Harn HJ, Ho LI, Chang JY, Wu CW, Jiang SY, Lee HS, Lee WH: Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 1995;75:1065-1071.
23. Washington K, Gottfried MR, Telen MJ: Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994;25:1043-1049.
24. Rall CJ, Rustgi AK: CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 1995;55: 1831-1835.
25. Takada M, Yamamoto M, Saitoh Y: The significance of CD44 in human pancreatic cancer. High expression of CD44 in human pancreatic adenocarcinoma. Pancreas 1994;9:748-752.
26. Takada M, Yamamoto M, Saitoh Y: The significance of CD44 in human pancreatic cancer: II. The role of CD44 in human pancreatic adenocarcinoma invasion. Pancreas 1994;9:753-757.
27. Matsumura Y, Hanbury D, Smith J, Tarin D: Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 1994;308:619-624.
28. Dall P, Heider KH, Hekele A, von Minckwitz G, Kaufmann M, Ponta H, Herrlich P: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994;54:3337-3341.
29. Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G, Reinthaller A: Prognostic value of CD44 splice varients in human stage II cervical cancer. Eur J Cancer 1995;31A:1706-1709.
30. Uhlsteidl M, Mullerholzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O: Prognostic value of CD44 splice varient expression in ovarian cancer. Oncology 1995;52:400-406.
31. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, Yajima A: Expression of CD44 in normal human versus tumor endometrial tissues: Possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994;54:3922-3928.
32. Liu AY: Expression of CD44 in prostate cancer cells. Cancer Lett 1994;76:63-69.
33. Lokeshwar BL, Lokeshwar VB, Block NL: Expression of CD44 in prostate cancer cells: Association with cell proliferation and invasive potential. Anticancer Res 1995;15:1191-1198.
34. Welsh CF, Zhu D, Bourguignon LYW: Interaction of CD44 varient isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-612.
35. Stevens JW, Palechek PL, Griebling TL, Midura RJ, Rokhlin OW, Cohen MB: Expression of CD44 isoforms in human prostate tumor cell lines. Prostate 1996;28:153-161.
36. Zhang S-H, Sakamoto H, Takenaka I: Accumulation of p53 and expression of CD44 in human prostate cancer and benign prostatic hyperplasia: An immunohistochemical study. Br J Urol 1996;77:441-444.
37. DiGiuseppe JA, Redston MS, Hruban RH: p53-Independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1996;147:884-887.
38. Kallakury BVS, Yang F, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma: Correlation with tumor grade and ploidy. Cancer 1996;78:1461-69.
39. Friedrichs K, Franke F, Lisboa B, Kugler G, Ingbert G, Terpe H, Holzel F, Maass H, Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-5433.
40. Terpe HJ, Christiansen H, Gonzalez M, Berthold F, Lampert F: Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 1995;31A:549-552.
41. Ohori NP, Coppola D, Landrenau RJ: CD44v6 expression in primary bronchioalveolar carcinoma and conventional pulmonary adenocarcinoma. Mod Pathol 1996;9:507-512.
42. Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ: Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 1995;153:2025-2028.
43. Figge J, Del Rosario AD, Gerasimov G, Dedov I, Bronstein M, Troshina K, Alexandrova G, Kallakury BVS, Bui HX, Bratslavsky G, Ross JS: Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp Mol Pathol 1994;61:203-211.
44. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL, Rosada C: Expression of CD44 in human lung tumors. Cancer Res 1994;54:1381-1387.
45. Yaegashi N, Fujita N, Yajima A, Nakamura M: Menstrual cycle dependent expression of CD44 in normal human endometrium. Hum Pathol 1995;26:862-865.